Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics reported first quarter 2026 results showing no collaboration revenue compared with $109,164k a year earlier, leading to a net loss. Operating expenses fell to $23,684k from $34,988k as research and development and general and administrative costs both declined.
The company posted a net loss of $21,645k, versus net income of $76,560k in the prior-year quarter, with basic and diluted net loss per share of $0.11 compared with earnings of $0.89. Cash and cash equivalents were $51,048k, and total assets rose to $326,553k with stockholders' equity of $264,744k.
Century Therapeutics, Inc. reported a net loss of $21.6 million for the three months ended March 31, 2026, compared with net income of $76.6 million a year earlier, when results included a large one-time collaboration revenue from Bristol-Myers Squibb.
Collaboration revenue was $0 this quarter versus $109.2 million in the prior-year period. Research and development expenses declined to $17.1 million from $26.6 million, and general and administrative expenses fell to $6.6 million from $8.4 million, reflecting cost controls and portfolio focus.
Cash, cash equivalents and investments totaled about $217.0 million, and management believes this will fund operations into the first quarter of 2029. During the quarter, the company closed a $126.4 million private placement, significantly increasing shares outstanding while supporting development of lead iPSC-derived cell therapy programs CNTY-813, CNTY-308 and CNTY-101.
Century Therapeutics, Inc. Senior Vice President of Finance & Operations Douglas Carr completed an automatic sale of 264 shares of common stock at $2.341 per share. The sale was made solely to cover tax withholding obligations arising from the vesting of restricted stock units and was not at his discretion.
Following this tax-related sale, Carr directly holds 506,997 shares of Century Therapeutics common stock, indicating that the transaction represents a very small portion of his overall equity position.
Century Therapeutics, Inc. is holding its 2026 annual stockholders meeting virtually on June 11, 2026 at 9:00 a.m. Eastern Time. Stockholders of record on April 16, 2026, when 180,354,197 common shares were outstanding, can vote online.
Key items include electing two Class II directors through 2029, ratifying Ernst & Young LLP as independent auditor for 2026, and approving an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, plus a related adjournment proposal. The proxy also outlines board independence and committee structure, recent R&D milestones in cell therapies, a January 2026 securities purchase agreement with approximately $135 million in gross proceeds, and detailed 2025 executive and director compensation, including a $2.38 million total package for the CEO.
Century Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on June 11, 2026. Shareholders will vote on the election of two Class II directors, ratification of Ernst & Young LLP as auditor, and a proposed amendment to increase authorized common shares from 300,000,000 to 450,000,000. The meeting record date is April 16, 2026. Recent corporate highlights note IND-enabling progress across several cell therapy programs and a securities purchase that generated approximately $135 million in gross proceeds.
Century Therapeutics, Inc. director Martin Patrick Murphy received a grant of stock options as equity compensation. The award covers 88,000 options for Common Stock with an exercise price of $0.592 per share, expiring on December 9, 2035.
The options were granted in connection with his appointment as a director and will vest in equal monthly installments over 36 months, conditioned on his continued service to the company. After this grant, he directly holds 88,000 stock options.
Century Therapeutics, Inc. director Martin Patrick Murphy filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing lists him as a director of Century Therapeutics but shows no reported transactions or current derivative positions in the structured data provided.
Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported a routine tax-related share withholding. On 2026-04-01, 1,365 shares of common stock were withheld at $2.19 per share to satisfy tax obligations from vesting restricted stock units, not an open-market sale.
After this transaction, Cowan directly held 1,175,680 shares of common stock. An additional 10,697 shares were held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Century Therapeutics, Inc. filed a current report describing updates to its shelf registration and at-the-market equity program. A new Form S-3 shelf registration statement became effective on January 9, 2026, replacing the prior shelf. The company also filed a new prospectus supplement dated March 26, 2026 for its existing at-the-market equity offering program with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent under a July 1, 2022 Sales Agreement. Under this program, the company may issue and sell shares of common stock having an aggregate offering price of up to $150,000,000. It has already sold shares with an aggregate offering price of $18,380,259, leaving up to $131,619,741 of common stock available for future sale under the program.